Literature DB >> 25189451

Endoscopic treatment for dysplastic Barrett's esophagus.

Christine Kestens1, Peter D Siersema.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25189451     DOI: 10.1007/s00268-014-2764-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  8 in total

1.  Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection.

Authors:  Mario Anders; Christina Bähr; Muhammad Abbas El-Masry; Andreas H Marx; Martin Koch; Stefan Seewald; Guido Schachschal; Andreas Adler; Nib Soehendra; Jakob Izbicki; Peter Neuhaus; Heiko Pohl; Thomas Rösch
Journal:  Gut       Date:  2014-01-03       Impact factor: 23.059

2.  Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study.

Authors:  K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman
Journal:  Gastroenterology       Date:  2013-03-28       Impact factor: 22.682

Review 3.  Endoscopic treatments for dysplastic Barrett's esophagus: resection, ablation, what else?

Authors:  Charumathi Raghu Subramanian; George Triadafilopoulos
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

4.  Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus.

Authors:  David I Fudman; Charles J Lightdale; John M Poneros; Gregory G Ginsberg; Gary W Falk; Maureen Demarshall; Milli Gupta; Prasad G Iyer; Lori Lutzke; Kenneth K Wang; Julian A Abrams
Journal:  Gastrointest Endosc       Date:  2014-02-22       Impact factor: 9.427

5.  Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Authors:  M Sikkema; C W N Looman; E W Steyerberg; M Kerkhof; F Kastelein; H van Dekken; A J van Vuuren; W A Bode; H van der Valk; R J T Ouwendijk; R Giard; W Lesterhuis; R Heinhuis; E C Klinkenberg; G A Meijer; F ter Borg; J W Arends; J J Kolkman; J van Baarlen; R A de Vries; A H Mulder; A J P van Tilburg; G J A Offerhaus; F J W ten Kate; J G Kusters; E J Kuipers; P D Siersema
Journal:  Am J Gastroenterol       Date:  2011-05-17       Impact factor: 10.864

6.  Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated.

Authors:  Wouter L Curvers; Fiebo J ten Kate; Kausilia K Krishnadath; Mike Visser; Brenda Elzer; Lubertus C Baak; Clarisse Bohmer; Rosalie C Mallant-Hent; Arnout van Oijen; Anton H Naber; Pieter Scholten; Olivier R Busch; Harriët G T Blaauwgeers; Gerrit A Meijer; Jacques J G H M Bergman
Journal:  Am J Gastroenterol       Date:  2010-05-11       Impact factor: 10.864

7.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.

Authors:  K Nadine Phoa; Frederike G I van Vilsteren; Bas L A M Weusten; Raf Bisschops; Erik J Schoon; Krish Ragunath; Grant Fullarton; Massimiliano Di Pietro; Narayanasamy Ravi; Mike Visser; G Johan Offerhaus; Cees A Seldenrijk; Sybren L Meijer; Fiebo J W ten Kate; Jan G P Tijssen; Jacques J G H M Bergman
Journal:  JAMA       Date:  2014-03-26       Impact factor: 56.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.